Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025)
Keros Therapeutics (KROS) posted Free Cash Flow of -$28.8 million for Q4 2025, down 736.74% on a QoQ basis from $4.5 million in Q3 2025, and up 37.71% year-over-year from -$20.9 million in Q4 2024.
Keros Therapeutics (KROS) Free Cash Flow (2019 - 2025) Analysis & Trends
Keros Therapeutics' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$28.8 million for Q4 2025.
- Quarterly Free Cash Flow rose 37.71% year-over-year to -$28.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.0 million (up 165.08% YoY) and the FY2025 annual result came in at $106.0 million, up 165.08% from the prior year.
- Free Cash Flow was -$28.8 million for Q4 2025 at Keros Therapeutics, down from $4.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at $160.6 million in Q1 2025 and bottomed at -$46.3 million in Q4 2024.
- A 5-year average of -$15.9 million and a median of -$25.0 million in 2022 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2023 — Free Cash Flow plunged 2162.62% — and 2025, when it soared 458.58%.
- Keros Therapeutics' Free Cash Flow stood at -$19.7 million in 2021, then declined by 9.03% to -$21.5 million in 2022, then fell by 20.9% to -$26.0 million in 2023, then tumbled by 78.07% to -$46.3 million in 2024, then surged by 37.71% to -$28.8 million in 2025.
- Business Quant data shows KROS's Free Cash Flow at -$28.8 million in Q4 2025, $4.5 million in Q3 2025, and -$30.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 158.09 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -354.95 Mn |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - | -28.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -28.84 Mn |
| Dec 31, 2025 | -28.84 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Sep 30, 2025 | 4.53 Mn |
| Jun 30, 2025 | -30.34 Mn |
| Jun 30, 2025 | -30.34 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Mar 31, 2025 | 160.61 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Dec 31, 2024 | -46.30 Mn |
| Sep 30, 2024 | -30.89 Mn |
| Sep 30, 2024 | -30.89 Mn |
| Jun 30, 2024 | -40.83 Mn |
| Jun 30, 2024 | -40.83 Mn |
| Mar 31, 2024 | -44.79 Mn |
| Mar 31, 2024 | -44.79 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Dec 31, 2023 | -26.00 Mn |
| Sep 30, 2023 | -34.53 Mn |
| Sep 30, 2023 | -34.53 Mn |